Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia
β Scribed by Srdan Verstovsek; Hagop Kantarjian; Taghi Manshouri; Susan O'Brien; Stefan Faderl; Moshe Talpaz; Jorge Cortes; Maher Albitar
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 105 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during
## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression β₯ Grade 3, requiring interruption of thera
## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea